CagriSema outperforms Wegovy in Landmark Trial,Novo Nordisk Aims for Regulatory Approval
Table of Contents
Novo Nordisk is poised to reshape the obesity and type 2 diabetes treatment landscape with CagriSema,a new combination drug demonstrating substantially superior results to its blockbuster Wegovy in a pivotal phase 3 study. The promising data arrives at a crucial juncture for the Danish pharmaceutical giant, as it navigates increasing market competition and investor concerns.
Just days before the release of its annual financial results, Novo Nordisk shared the encouraging findings on Monday, signaling a potential turning point for the company. The results indicate that CagriSema could surpass Wegovy as the preferred treatment option in an increasingly competitive market.
CagriSema Demonstrates Clear Advantage Over Wegovy
The REIMAGINE 2 study focused on the efficacy of CagriSema in patients with type 2 diabetes. The drug, a combination of semaglutide and the long-acting amylin receptor agonist cagrilintide, yielded markedly better outcomes than treatment with semaglutide alone – the active ingredient in Wegovy.
After 68 weeks, patients receiving the combination therapy experienced an average weight loss of 14.2 percent, compared to 10.2 percent in the group treated with semaglutide. Furthermore, CagriSema exhibited superior performance in blood sugar control, as measured by HbA1c levels. Experts particularly highlighted the sustained weight loss observed over the course of the year-long study, indicating a continued affect without the typical plateau seen in other treatments.
Key study results:
- Weight loss (CagriSema): 14.2% at 68 weeks
- Weight loss (Wegovy): 10.2% at 68 weeks
- HbA1c reduction (CagriSema): 1.91 percentage points
- Significant Weight Loss: Up to 43% of patients lost at least 15% of their body weight.
Based on these compelling results, novo Nordisk is initiating discussions with regulatory bodies regarding the drug’s application for use in type 2 diabetes. An application for use in weight management has already been submitted to the US Food and Drug Governance (FDA) in December 2025.
The positive trial data emerges at a critical time for Novo Nordisk. While the company’s share price saw a modest recovery on Monday following initial declines, it remains down approximately 37 percent over the past twelve months. This investor hesitancy stems from growing anxieties surrounding pricing pressures within the obesity market.
“Falling prices in the US and increased competition are dampening expectations for overall market volume,” one analyst noted. Reports suggest that experts anticipate Novo Nordisk may forecast a decline in both sales and operating profit for 2026. In this context, CagriSema is increasingly viewed as a vital catalyst for maintaining long-term market leadership.
Focus Shifts to Quarterly Earnings and Wegovy’s oral Formulation
Investor attention is now directed toward Novo Nordisk’s fourth-quarter 2025 earnings report,scheduled for release on Wednesday,February 4,2026,prior to the stock market opening in Copenhagen. beyond the standard financial figures, the outlook for 2026 and the progress of prescription numbers for the new oral formulation of Wegovy will be closely scrutinized.
the company’s future trajectory hinges on its ability to navigate these challenges and capitalize on the potential of CagriSema. A recent analysis, released on February 2nd, urges Novo Nordisk shareholders to carefully consider their positions, questioning whether now is the time to invest or divest. the analysis suggests the latest figures demand immediate action.
